Description
5-Chloro-αMT, 5-Chloro-α-methyltryptamine, PAL-542, 5-Cl-αMT
Product information
IUPAC 1-(5-Chloro-1H-indol-3-yl)propan-2-amine
Synonyms 5-Chloro-αMT, 5-Chloro-α-methyltryptamine, PAL-542, 5-Cl-αMT
Formal Name 1-(5-Chloro-1H-indol-3-yl)propan-2-amine
CAS 712-07-2
Formula C11H13ClN2
Molecular Weight 208.69 g·mol−1
Purity 99.0 % min.
Formulations A neat solid, Powder
Solubility
- DMF: 25 mg/ml
- DMF:PBS (pH 7.2) (1:1): 0.5 mg/ml
- DMSO: 20 mg/ml
- Ethanol: 10 mg/ml
Shipping & Storage Information
5-Chloro-αMT, 5-Chloro-α-methyltryptamine, PAL-542, 5-Cl-αMT
5-Chloro–methyltryptamine (5-Chloro-αMT), also known as PAL-542, is a derivative of α-methyltryptamine, which is a serotonin-diopamine releasing agent. It has been shown in animal models to be useful in treating cocaine dependence.
In vitro release of various chemicals, such as serotonin, dopamine, and norepinephrine, by 5-chloro-MT was observed in rat synaptosomes. The EC50 values of 5-chloro-αMT were found to be 16 nM, 54 nM, and 3434 nM, with a DA/NE ratio of 63.6, indicating that it is a well-balanced SDRA. It has also been shown that it can act as a powerful agonist of the 5-HT2A receptor.
It was previously known that 5-chloro-αMT was not able to produce intracranial effects in rats or monkeys. In a study of rhesus monkeys, it was found that the lack of norepinephrine release does not affect the abuse potential of monoamine-releasing agents. It was also found that the reduction of this activity does not affect the efficacy of these drugs in treating cocaine self-administration.
It is believed that SDRAs such as PAL-542 could potentially produce fewer side effects than those of standard drugs, which could make them more useful in treating cocaine dependence. These side effects include anxiety and insomnia, and could also be triggered by other factors such as exposure to sunlight.
5-chloro-αMT, which is a derivative of 5-fluoro-α-methyltryptamine, is a potent inhibitor of the serotonin-norepinephrine complex. It has similar structural properties to the other MAO-A compounds, such as 5-HT2A receptor agonists and SNDRA. Its activity could render it dangerous in combination with other drugs, such as PMA.
Another type of MAO-A compound, α-ethyltryptamine, is a close relative of 5-chloro-αMT and 5-hydroxytryptamine. It has been known to cause long-lasting neurotoxicity in rats. This suggests that other tryptamines, such as 5-chloro-αMT, could also be susceptible to the same effects.
5-chloro-αMT is a 5-HT2A receptor agonist that can potentially be used for the treatment of psychedelic effects. In rats, it can trigger a head-twitch response. This drug is also known to be associated with the effects of LSD.
The toxicological and physiological properties of this compound has not been analyzed. Usage of this Chemical should be for research and forensic purposes only.
WARNING This product is not for human or veterinary use.
This product is only available to persons of 21 years old and above.
Hazard statement(s)
H302 | Harmful if swallowed |
H315 | Causes skin irritation |
H319 | Causes serious eye irritation |
H332 | Harmful if inhaled |
H335 | cause respiratory irritation |
H336 | cause drowsiness or dizziness |
Precautionary statement(s) | |
P264 | Wash hands thoroughly after handling |
P280 | protective gloves/protective clothing/eye protection/face protection |
P305 + P351 + P338 | IF IN EYES: Rinse cautiously with for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. |
P337 + P313 | If eye irritation persists: Get medical advice/attention |
P261 | Avoid breathing dust/ fume/ gas/ mist/ vapors/ spray |
P271 | Use only outdoors or in a well-ventilated area |
P304 + P340 | IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing |
P312 | Call a POISON CENTER or doctor/physician if you feel unwell |
P403 + P233 | Store in a well-ventilated place. Keep container tightly closed |
P405 | Store locked up |
P501 | Dispose of contents/container to a licensed disposal company |
Reviews
There are no reviews yet.